What AI Companies Need to Know About Clinical Development

Most AI investment in biopharma has gone into drug discovery: target identification, molecule prediction, and drug-screening optimization, for example. This is well-funded territory, and increasingly well-served. Once a promising treatment is discovered, though, there can still be a decade or more of in-human clinical trials, where the treatment faces its ultimate test: proving its efficacy and safety in diverse populations. This is the longer, more expensive part of the process, and where many high-stakes programs fail. AI has played a relatively minor role here so far. That’s where useful AI work is.